
Because of its location on the hands and feet, palmoplantar pustulosis can have a significant impact on quality of life. A recent Austrian study using data from the Psoriasis Registry Austria analysed data collected between 1997 and 2024 highlighting patient demographics and the effect of a variety of treatments.
Seventy-four percent of affected patients were women, and the majority were smokers. Their mean DLQI was over 11.
There was a considerable delay in diagnosis, with many people being initially misdiagnosed as hand eczema. The characteristic pustules, which leave rusty red dots, should aid earlier recognition. Half of the patients had concomitant plaque psoriasis and 20% psoriatic arthritis.
Conventional treatments had included emollients, topical steroids, tar, phototherapy, (particularly hand and foot PUVA); retinoids, apremilast, fumaric acid esters and methotrexate. Across the cohort (all treatment types combined), the median time to discontinuation was 6 months, indicating either primary or secondary treatment failure or discontinuation due to side effects.
Eventually, almost fifty percent of their cohort received a biological agent. Ustekinumab, which targets IL-12 and IL-23 seemed to be the most effective therapy with a median drug survival time of two and a half years. Twenty percent of patients had off-label dosing (either more frequent dosing or dose escalation).
Since 2024 in many countries ustekinumab biosimilar drugs have become available and may be as much as 25% of the cost of the originator drug. In the UK, the annual cost estimate is £1200. This is similar to the cost of twice weekly hand and foot PUVA for 6 weeks. Perhaps it is time to convince the funding bodies that earlier introduction of the newer cost effective biosimilar IL-12 and -23 blockers is due.
Dr Ian Coulson, Dermatologist and DermNet Editor-in-Chief
Graier T, Bordag N, Weger W, et al. Real-world evidence on palmoplantar pustulosis: patient characteristics, diagnostic challenges and predictive factors for treatment survival - a retrospective registry study. Br J Dermatol. 2026;194(1):77-85. Journal
Post your comment
Comments
No one has commented on this page yet.